Table 1 FDA recommendations [19]
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Genotype | Treatment | Duration (weeks) |
|---|---|---|
1 | Harvoni | 12 |
Olysio + Sovaldi with or without Ribavirin | 12 (no cirrhosis), 24 (cirrhosis) | |
Viekira Pak + Ribavirin | 12 (no cirrhosis), 24 (cirrhosis) | |
Sovaldi + Peginterferon + Ribavirin | 12 | |
2 | Sovaldi + Ribavirin | 12 |
3 | Sovaldi + Ribavirin | 24 |